MetrumRG collaborated on a routine Phase 2/3 program involving four PK/PD models to simulate dose, regimen, and Phase 3 trial design performance. The project team included five cross-discipline members from clinical pharmacology, pharmacometrics, and statistics.
Challenge
The scope of the project—thousands of simulations supporting strategic development decisions—would traditionally require 2–3 months to complete, posing a delay risk to downstream clinical decision-making.
Solution
By utilizing Metworx’s parallel processing capabilities and shared data repository, each team member independently optimized their own compute clusters to conduct high-performance analysis simultaneously.
Results
The team applied model-based methods to explore development strategy through simulation, completing the work in just 2–3 weeks. Metworx enabled significant efficiencies and shortened the critical development timeline.
Impact
Metworx reduced the Phase 2/3 development timeline by more than two months, accelerating time-to-decision and enabling the team to apply strategic modeling at scale—without compromising reproducibility or validation integrity.
Stay focused on science. Leave the infrastructure to Metworx
Avoid costly delays and get to insights faster with a proven, compliant, scalable platform.
.png?width=348&height=84&name=Logo_Full_KO%20(1).png){kind=logo}
